Sumitomo Mitsui Trust Group, Inc. and Amova Asset Management Co., Ltd. filed an amended beneficial ownership report with the SEC on October 29, 2026, disclosing a combined holding of 1,689,107 shares of Arcturus Therapeutics Holdings Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Sumitomo Mitsui Trust Group, Inc. and Amova Asset Management Co., Ltd. each report beneficial ownership of 1,689,107 shares of Arcturus Therapeutics Holdings Inc. common stock.
  • Ownership percentage: The reported position represents 5.9% of the outstanding class of common stock, par value $0.001 per share (CUSIP 03969T109).
  • Voting and dispositive power: Both reporting persons report zero sole voting power and zero sole dispositive power; shared voting and shared dispositive power are each listed at 1,689,107 shares.
  • Subsidiary named: The filing identifies Amova Asset Management Americas, Inc. as the subsidiary that acquired and holds the securities on behalf of the parent entities, classified as an investment adviser.
  • Amendment number: This filing is Amendment No. 3 to a previously filed beneficial ownership statement, triggered by an event dated September 30, 2026.
  • Reporting persons' domicile: Both Sumitomo Mitsui Trust Group, Inc. and Amova Asset Management Co., Ltd. are organized under the laws of Japan.

Ownership Structure and Subsidiary Arrangements at Arcturus Therapeutics

According to the filing, Sumitomo Mitsui Trust Group, Inc., headquartered at 1-4-1 Marunouchi, Chiyoda-ku, Tokyo, is classified as a parent holding company, a non-U.S. institution, and a group for purposes of the applicable SEC rules. Amova Asset Management Co., Ltd., located at Azabudai Hills Mori JP Tower, 1-3-1 Azabudai, Minato-ku, Tokyo, is classified simultaneously as an investment adviser, a parent holding company, and a non-U.S. institution. Arcturus Therapeutics Holdings Inc. is a San Diego-based biotechnology company with principal executive offices at 10285 Science Center Drive, San Diego, California 92121, operating in the field of RNA medicines.

The filing discloses that the 1,689,107 shares "are owned, or may be deemed to be beneficially owned, by their subsidiary Amova Asset Management Americas, Inc.," which the filing classifies as an investment adviser. Both parent entities report no sole power to vote or dispose of the shares; all reported voting and dispositive authority is shared. The certification included in the filing states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

The filing, signed on October 29, 2026 by Hideaki Takamiya, Senior Manager of Risk Management Dept for Sumitomo Mitsui Trust Group, Inc., and by Atsushi Ohya, Head of Business Regulatory Compliance for Amova Asset Management Co., Ltd., represents the third amendment to the group's beneficial ownership statement covering shares of NASDAQ:ARCT common stock.

What Was Disclosed

Sumitomo Mitsui Trust Group, Inc. and Amova Asset Management Co., Ltd. filed Amendment No. 3 to their beneficial ownership statement, reporting 1,689,107 shares, or 5.9%, of Arcturus Therapeutics Holdings Inc. common stock held through subsidiary Amova Asset Management Americas, Inc. as of September 30, 2026.